Ocera Therapeutics Inc. (NASDAQ:OCRX) generated $45,000 in revenue for the three months ended March 31, 2014 from royalty revenue from a licensing agreement compared to no revenue for the three months ended March 31, 2013. Ocera Therapeutics Inc. (NASDAQ:OCRX) weekly performance is -3.92%. On last trading day company shares ended up $7.35. Analysts mean target price for the company is $22.50. Ocera Therapeutics Inc. (NASDAQ:OCRX) distance from 50-day simple moving average (SMA50) is -27.69%.
Esperion Therapeutics Inc. (NASDAQ:ESPR) Net loss was $7.9 million for the first quarter of 2014 compared to a net loss of $4.2 million for the first quarter of 2013. Esperion Therapeutics Inc. (NASDAQ:ESPR) shares fell -5.55% in last trading session and ended the day on $13.78. ESPR return on assets is -54.80%.Esperion Therapeutics Inc. (NASDAQ:ESPR) quarterly performance is -13.17%.
Cellular Dynamics International (NASDAQ:ICEL) was upgraded by equities research analysts at Leerink Swann from a “market perform” rating to an “outperform” rating in a research note issued to investors on Wednesday, TheFlyOnTheWall.com reports. The firm currently has a $17.00 target price on the stock. Leerink Swann’s target price points to a potential upside of 53.57% from the stock’s previous close. Cellular Dynamics International Inc. (NASDAQ:ICEL) shares moved down -5.15% in last trading session and was closed at $11.42, while trading in range of $10.91 – $12.05. Cellular Dynamics International Inc. (NASDAQ:ICEL) year to date (YTD) performance is -30.79%.
For the year ended December 31, 2013 Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) recognized $10,000 in license revenues compared to $100,000 in license revenues recognized during the prior year. Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) ended the last trading day at $4.81. Company weekly volatility is calculated as 13.22% and price to cash ratio as 2.79.Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) showed a negative weekly performance of -25.89%.
Trovagene, Inc. (NASDAQ:TROV), a developer of cell-free molecular diagnostics, on 14 may announced that data from a study of its precision cancer monitoring technology, conducted by MD Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center, will be presented during a poster session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). An additional abstract, submitted by Filip Janku, M.D., Ph.D., of The University of Texas MD Anderson Cancer, has been accepted for publication in 2014 ASCO Annual Meeting Proceedings, a Journal of Clinical Oncology. TrovaGene Inc. (NASDAQ:TROV) weekly performance is -23.08%. On last trading day company shares ended up $3.70. Analysts mean target price for the company is $10.00. TrovaGene Inc. (NASDAQ:TROV) distance from 50-day simple moving average (SMA50) is -31.38%.
Leave a Reply